MMMichael MacIsaac

Michael MacIsaac

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michael MacIsaac has a total of 61 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Long-Term Outcomes of a Decentralized, Nurse-Led, Statewide Model of Care for Hepatitis C Among People in Prison in Victoria, Australia

    by Michael B MacIsaac, Timothy Papaluca, Lucy McDonald, Anne Craigie, Amy Edwards, Chloe Layton, Annabelle Gibson, Rebecca J Winter, Kiran Iyer, Abigail Sim, et al.

    Background: Prisons provide a key strategic opportunity to upscale hepatitis C testing and treatment in a high-prevalence setting and are crucial for elimination efforts. Methods: A decentralized, statewide, nurse-led model of care offering hepatitis C treatment for people in prison was implemented in Victoria, Australia, in 2015. The program provides hepatitis C care at all 14 adult prisons in the jurisdiction. We prospectively evaluated treatment uptake between 1 November 2015 and 31 December 2021. Data on all people in prison who were treated were recorded in a clinical database. Primary outcomes were the number of people in prison who completed hepatitis C treatment with direct-acting antiviral (DAA) therapy and the proportion who achieved sustained virologic response (SVR12). Results: A total of 3133 DAA treatment courses were prescribed to 2768 people in prison. The proportion of total Victoria DAA prescriptions the program was responsible for increased from 6% in 2016 to a peak of 23% in 2020. The median age was 39 years, 91% were male, and 9% had cirrhosis. Few (20%) had previously engaged in hepatitis C care in the community only 6% were treatment experienced. Complete follow-up data were available for 1757 of 2768 (63%) treated, with 1627 of 1757 (93%) achieving SVR12. Conclusions: A decentralized, nurse-led, statewide model of care was highly effective in treating large numbers of people in prison with hepatitis C and achieved high rates of SVR12. Nurse-led prison programs are playing a crucial role in eliminating hepatitis C as a public health threat in Australia.


  • Point-of-care HCV RNA testing improves hepatitis C testing rates and allows rapid treatment initiation among people who inject drugs attending a medically supervised injecting facility

    by Michael B MacIsaac, Bradley Whitton, Jenine Anderson, Shelley Cogger, Dylan Vella-Horne, Matthew Penn, Anthony Weeks, Kasey Elmore, David Pemberton, Rebecca J Winter, et al.


  • Open Access

    Eliminating hepatitis C in Australia: a novel model of hepatitis C testing and treatment for people who inject drugs at a medically supervised injecting facility

    by Michael B MacIsaac, Bradley Whitton, Adrian Hubble, Shelley Cogger, Matthew Penn, Anthony Weeks, Kasey Elmore, David Pemberton, Jenine Anderson, Rebecca Howard, et al.

    ObjectiveTo evaluate the feasibility of testing and treating people who inject drugs at a supervised injecting facility for hepatitis C virus (HCV) infection. DesignRetrospective cohort study. Setting, participantsPeople who inject drugs who attended the Melbourne supervised injecting facility, 30 June 2018 - 30 June 2020. Main outcome measuresProportion of people tested for hepatitis C; proportions of people positive for anti-HCV antibody and HCV RNA, and of eligible people prescribed direct-acting antiviral (DAA) treatment; sustained virological response twelve weeks or more after treatment completion. ResultsOf 4649 people who attended the supervised injecting facility during 2018-20, 321 were tested for hepatitis C (7%); 279 were anti-HCV antibody-positive (87%), of whom 143 (51%) were also HCV RNA-positive. Sixty-four of 321 had previously been treated for hepatitis C (20%), 21 had clinically identified cirrhosis (7%), eight had hepatitis B infections (2%), and four had human immunodeficiency virus infections (1%). In multivariate analyses, people tested for hepatitis C were more likely than untested clients to report psychiatric illness (adjusted odds ratio [aOR], 9.65; 95% confidence interval [CI], 7.26-12.8), not have a fixed address (aOR, 1.59; 95% CI, 1.18-2.14), and to report significant alcohol use (aOR, 1.57; 95% CI, 1.06-2.32). The median number of injecting facility visits was larger for those tested for hepatitis C (101; interquartile range [IQR], 31-236) than for those not tested (20; IQR, 3-90). DAA treatment was prescribed for 126 of 143 HCV RNA-positive clients (88%); 41 of 54 with complete follow-up data were cured (76%). ConclusionsPeople who attend supervised injecting facilities can be tested and treated for hepatitis C on site. Models that provide streamlined, convenient hepatitis C care promote engagement with treatment in a group in which the prevalence of hepatitis C is high.


  • Open Access

    Care Navigation Increases Initiation of Hepatitis C Treatment After Release From Prison in a Prospective Randomized Controlled Trial: The C-LINK Study

    by Timothy Papaluca, Anne Craigie, Lucy McDonald, Amy Edwards, Rebecca Winter, Annabelle Hoang, Alex Pappas, Aoife Waldron, Kelsey McCoy, Mark Stoove, et al.

    Prison-based hepatitis C treatment is safe and effective; however, many individuals are released untreated due to time or resource constraints. On community re-entry, individuals face a number of immediate competing priorities, and in this context, linkage to hepatitis C care is low. Interventions targeted at improving healthcare continuity after prison release have yielded positive outcomes for other health diagnoses; however, data regarding hepatitis C transitional care are limited. We conducted a prospective randomized controlled trial comparing a hepatitis C care navigator intervention with standard of care for individuals released from prison with untreated hepatitis C infection. The primary outcome was prescription of hepatitis C direct-acting antivirals (DAA) within 6 months of release. Forty-six participants were randomized. The median age was 36 years and 59% were male. Ninety percent (n = 36 of 40) had injected drugs within 6 months before incarceration. Twenty-two were randomized to care navigation and 24 were randomized to standard of care. Individuals randomized to the intervention were more likely to commence hepatitis C DAAs within 6 months of release (73%, n = 16 of 22 vs 33% n = 8 of 24, P < .01), and the median time between re-entry and DAA prescription was significantly shorter (21 days [interquartile range {IQR}, 11–42] vs 82 days [IQR, 44–99], P = .049). Care navigation increased hepatitis C treatment uptake among untreated individuals released from prison. Public policy should support similar models of care to promote treatment in this high-risk population. Such an approach will help achieve hepatitis C elimination as a public health threat.


  • Anti-TNFα Induction Therapy for Patients With Active Inflammatory Bowel Disease During Pregnancy: A Case Series

    by Michael B MacIsaac, Mette Julsgaard, Emma Flanagan, Stephanie Rowe, Alyson L Ross, Richard B Gearry, Peter R Gibson, Sally J Bell

    Inflammatory bowel disease (IBD) commonly affects women during their peak reproductive years.1,2 However, safe and appropriate management of IBD during pregnancy still poses a challenging scenario. The negative influence of disease activity on birth outcomes is well established,1,2 with remission prior to conception and throughout pregnancy crucial for favorable pregnancy outcomes.1,2 Infliximab and adalimumab are antitumour necrosis factor α (TNFα) agents that effectively induce remission and improve clinical outcomes in IBD.3 These therapies are IgG1 proteins, which are transferred across the placenta from the second trimester of pregnancy.4 At term, infant drug concentrations are greater than those in the mother,5, 6 raising concerns about increased rates of infections in infants. Despite the growing body of evidence suggesting that it is safe to continue anti-TNFα therapy in pregnancy,6 there are currently limited data on maternal and neonatal outcomes in women requiring anti-TNFα induction during pregnancy. In this case series, we aimed to address this issue.


  • Prevalence and Characteristics of Interpersonal Violence in People Dying From Suicide in Victoria, Australia

    by Michael B MacIsaac, Lyndal Bugeja, Tracey Weiland, Jeremy Dwyer, Kav Selvakumar, George A Jelinek

    Victims of interpersonal violence are known to be at increased risk of suicidal ideation and attempts; however, few data exist on the impact that violence has on the risk of death from suicide. This study examined 2153 suicides (1636 males and 517 females) occurring between 2009 and 2012. Information was sourced from the Coroners Court of Victoria’s Suicide Register, a detailed database containing information on all Victorian suicides. Forty-two percent of women who died from suicide had a history of exposure to interpersonal violence, with 23% having been a victim of physical violence, 18% suffering psychological violence, and 16% experiencing sexual abuse. A large number of men who died from suicide had also been exposed to interpersonal violence, many of whom had perpetrated violence within the 6 weeks prior to their death. Targeted prevention, particularly removing barriers for men to seek help early after perpetrating violence is likely to have benefits in preventing suicide in both men and women.